Details for Patent: 11,298,349

Which drugs does patent 11,298,349 protect, and when does it expire?

Patent 11,298,349 protects COMETRIQ and CABOMETYX and is included in two NDAs.

This patent has thirty-eight patent family members in twenty-one countries.

Summary for Patent: 11,298,349

Title:	Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Abstract:	##STR00001## The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.
Inventor(s):	Wilson; Jo Ann (San Francisco, CA), Shah; Khalid (Half Moon Bay, CA)
Assignee:	Exelixis, Inc. (Alameda, CA)
Application Number:	17/170,275
Patent Claim Types: see list of patent claims	Composition; Compound; Process; Dosage form;

Drugs Protected by US Patent 11,298,349

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Exelixis	COMETRIQ	cabozantinib s-malate	CAPSULE;ORAL	203756-001	Nov 29, 2012		RX	Yes	No			Y
Exelixis	COMETRIQ	cabozantinib s-malate	CAPSULE;ORAL	203756-002	Nov 29, 2012		RX	Yes	Yes			Y
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-001	Apr 25, 2016		RX	Yes	No			Y
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-002	Apr 25, 2016		RX	Yes	No			Y
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-003	Apr 25, 2016		RX	Yes	Yes			Y

International Family Members for US Patent 11,298,349

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	085155
Australia	2012214322
Australia	2017204877
Australia	2019203745
Australia	2020273307
Australia	2022246429
Brazil	112013020362